No Prescription |
 |
 | ||
|
Estrofem Generic Estradiol |
|
| ||
No Prescription » Prescription Drugs 7 » Estrofem Generic Estradiol Medical Information: Estrofem« was especially developed and indicated for the treatment of oestrogen deficiency symptoms in women without a uterus with effective symptom relief and good tolerability (continuous therapy with calendar pack of 28 tablets containing 1mg 17b-oestradiol). As there is no increased risk of developing cancer of the uterus lining in women without a uterus they need not to take an additional progestogen. The drug is available in different dosages because a standardised unique dose is not optimal for every woman. Studies have demonstrated that after four weeks of treatment there is a significant reduction in hot flushes and other menopausal complaints. The administration of Estrofem« results in a significant increase of bone density. Estrofem« is an oestrogen only treatment for effective symptom relief and one of the options for osteoporosis prevention in hysterectomised women. Promotes growth and development of female reproductive system and secondary sex characteristics; affects release of pituitary gonadotropins; inhibits ovulation and prevents postpartum breast engorgement; conserves calcium and phosphorous and encourages bone formation; overrides stimulatory effects of testosterone. Buy Estrofem Generic Estradiol and other Prescription Drugs 7 products online at Medstore. Buy Online at Medstore - Click Here!
About Estrofem Generic Estradiol: Product Type: Prescription Drugs 7 Estrofem ( Generic Estradiol ) Estrofem (Generic Estradiol) Generic Estradiol 2mg 84 (3x 28)Tabs 28 Tabs Generic Estradiol Estrofem
View more Prescription Drugs 7 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
